Food Supplement 20070721-GX May Increase CD34+ Stem Cells and Telomerase Activity by Lin, Po-Cheng et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 498051, 8 pages
doi:10.1155/2012/498051
Research Article
Food Supplement20070721-GX May Increase CD34+
Stem Cells and Telomerase Activity
Po-Cheng Lin,1 Tzyy-Wen Chiou,2 Po-Yen Liu,3 Shee-PingChen,4 Hsin-IWang,5
Pi-ChunHuang,5 Shinn-ZongLin,1,6,7 and Horng-Jyh Harn8,9
1Center for Neuropsychiatry and Department of Neurosurgery, China Medical University Hospital, 2 Yuh-Der Road,
Taichung 40447, Taiwan
2Department of Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan
3Graduate Institute of Chinese Medicine, China Medical University, Taichung 40447, Taiwan
4Tzu Chi Stem Cells Centre, Buddhist Tzu Chi General Hospital, Hualien 97002, Taiwan
5Department of Stem Cell Applied Technology, Gwo Xi Stem Cell Applied Technology, Hsinchu 30261, Taiwan
6Graduate Institute of Immunology, China Medical University, Taichung 40447, Taiwan
7Department of Neurosurgery, China Medical University Beigan Hospital, Yunlin 65152, Taiwan
8Department of Pathology, China Medical University Hospital, 2 Yuh-Der Road, Taichung 40447, Taiwan
9Department of Medicine, China Medical University, Taichung 40447, Taiwan
Correspondence should be addressed to Shinn-Zong Lin, shinnzong@yahoo.com.tw and
Horng-Jyh Harn, duke harn@yahoo.com.tw
Received 25 May 2011; Revised 1 February 2012; Accepted 1 February 2012
Academic Editor: Michael J. Spinella
Copyright © 2012 Po-Cheng Lin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Few rejuvenation and antiaging markers are used to evaluate food supplements. We measured three markers in peripheral blood to
evaluate the antiaging eﬀects of a food supplement containing placental extract. Samples were evaluated for CD34+ cells, insulin-
like growth factor 1 (IGF1), and telomerase activity, which are all markers related to aging. To control the quality of this food
supplement, ﬁve active components were monitored. In total, we examined 44 individuals who took the food supplement from
1.2 months to 23 months; the average number of CD34+ cells was almost 6-fold higher in the experimental group compared with
the control group. Food supplement intake did not change serum IGF1 levels signiﬁcantly. Finally, the average telomerase activity
was 30% higher in the subjects taking this food supplement. In summary, our results suggest that the placental extract in the food
supplement might contribute to rejuvenation and antiaging.
1.Introduction
Human placenta, also called ziheche in Chinese, has been
used as a medicine in Korea and China for over 1,400
years due to its anti-aging and cosmetic properties [1]. In
traditional oriental medicine, human placental extract has
been used for wound healing. More recently, human pla-
cental extract was approved for treatment of abnormal liver
functionandmenopausalsymptomsandhasnoknowntoxic
eﬀects [2–4]. In both rodent and human cells in vitro,
placental extract induces signiﬁcant nitric oxide production,
which is an important cellular mediator of tissue repair [5].
Placental extract contains several enzyme inhibitors, anti-
coagulant proteins, and antioxidants [6–8]. Furthermore,
placental extract is a rich source of bioactive molecules such
as hormones, proteins, lipids, nucleic acids, glycosamino-
glycan, amino acids, vitamins, and minerals [2, 9]. It also
contains many uncharacterized compounds believed to have
various bioactivities involved in inhibition or delay of aging,
inﬂammation, sunburn, mutagenicity, anaphylaxis, and oxi-
dation [1].
Similar to human placenta, pig placenta has been used
as a source of biomedical material. In fact, freeze-dried pig
placenta contains equal or, in certain circumstances, higher
nutritive properties than human placenta [10].
Hematopoietic stem cells (HSCs) represent a long-lived
cell population that provides blood cells through hema-
topoiesis throughout the human lifespan. These cells are2 Journal of Biomedicine and Biotechnology
identiﬁed by the surface marker CD34+. Hematopoiesis is
regulated by a balance between self-renewal, proliferation,
and diﬀerentiation. The capacity of HSCs to maintain their
population through self-renewal replications throughout the
aging process may imply that the HSC population itself does
not age. However, diminishing proliferative capacity after
serial transplantation [11], repeated exposure to irradiation
[12] ,o ra g e - r e l a t e dl o s so ft e l o m e r i cD N A[ 13, 14] indicates
that the life of HSCs may be limited. In humans, CD34+
stem cells represent about 0.01% to 0.03% all cells in
peripheral blood [15]. Regulation of hematopoiesis is altered
during aging, impairing the ability of older people to
respond appropriately to the physiological demand for blood
cell replacement triggered by stimuli such as blood loss or
cytoreductive chemotherapy [16]. In the peripheral blood
and bone marrow, both the quantity and the clonogenic
capacity of HSCs decline with age [15, 17, 18]. Furthermore,
there are age-dependent diﬀerences in lineage maturation
and cell-cycle phases [19], as well as an accumulation of
genomicmutationsandanimbalanceincytokineproduction
[16]. Thus, HSCs are a key determinant in aging.
It is well established that a reduced concentration of
insulin-like growth factor 1 (IGF1) plays a role in extending
lifespanininvertebrates[20].Inmammalianevolution,IGF1
pathways have diverged from a single receptor to multiple
receptors and even more complicated pathways and regu-
latory networks [21]. Insulin, IGF1, and growth hormone
regulate metabolic pathways to control growth and diﬀer-
entiation [22]. This process depends mainly on the con-
centration of circulating IGF1. In mice, knocking out the
insulin receptor (IR) pathway reduces lifespan and increases
age-related diseases [23]. In contrast, both spontaneous and
targeted genetic disruptions of the GH/IGF pathway are
associated with small size (dwarﬁsm), numerous indices
of delayed aging, enhanced stress resistance, and a major
increase in lifespan in mice [24]. These results suggest a role
for the GH/IGF pathway in murine longevity. Furthermore,
caloric restriction, well known to extend lifespan and slow
down age-relatedpathology, is also associated with a reduced
concentration of circulating IGF1 in nematodes, fruit ﬂies,
and mice [25]. On the other hand, reducing the concentra-
tion of IGF1 in humans, although protective against cancer,
decreasesthe risk of cardiovasculardiseaseand diabetes [26].
Moreover, human aging is associated with a decline in GH
and IGF1 levels. It has been proposed that GH therapy may
r e v e r s es o m eo ft h ep h y s i o l o g i c a lf e a t u r e so fa g i n g[ 27].
Telomerase is pertinent to a cell’s potential for self-
renewal and is required for long-term cellular proliferation
and survival [28, 29]. Because human cells progressively lose
telomerase activity, telomeric DNA is lost during successive
roundsofDNAreplication.Shorteningoftelomereshasbeen
reported to correlate with cellular senescence [30, 31]. This
indicatesthatreplicatingcellsthatlosethetelomeraseneeded
to maintain telomeres will eventually senesce [32].
The aim of the present study was to evaluate the rejuve-
nation and anti-aging eﬀects of placental extract on healthy
individuals by determining CD34+ cell counts, serum IGF1
levels, and monocyte telomerase activity in peripheral blood.
2.MaterialsandMethods
2.1. Source of 20070721-GX. The ingredients of 20070721-
GX are pig placental extract, royal jelly, avocado oil, and
wheat germ oil. 20070721-GX is a proprietary formulation
availablefrom Gwo Xi Stem Cell Applied Technology, Inc. To
control the quality of each batch of the food supplement of
20070721-GX, the placental extract component is measured
by ELISA. The evaluation includes concentrations of pro-
gesterone (Pgt), estriol (E3), estradiol (E4), human choronic
gonadotropic (HCG), human placental lactogen (hPL), and
total protein (tPrt). For each batch, the concentrations are
10 ± 5mg/mLtPrt,30 ± 5ng/mLPgt,10± 5ng/mLE3,10±
5ng/mLE4,25±5mIU/mL HCG, and 0.15±0.1mg/LhPL.
Batchesthatﬁtthesesixindicatorsarechosenintochemistry,
manufacturing, and controls (CMCs) manufacturing for
standard operation and SGS examination.
2.2. Volunteers. This is a double-blind placebocontrolled
trial. This research project was approved by the Institutional
Review Board of China Medical University (DMR99-IRB-
32). Forty-four subjects were recruited from China Medical
University Hospital; 22 people have the product treatment
(20070721-GX group), and the other 22 people were placebo
treatment (Control group). The control group was 54.5%
male, and the 20070721-GX group was 50% male. The mean
agewas 43±16 years in the control group and 46±9y e a r si n
the 20070721-GX group. Basic characteristics of individual
subjects are listed in Tables 1 and 2.
2.3. Sample Collection. Individuals in the experimental
group took three capsules (20070721-GX or placebo) daily
for months. Peripheral blood samples from control and
20070721-GX subjects were drawn into BD Vacutainer CPT
Tubes (Becton, Dickinson and Co., Franklin Lakes, NJ).
Within 2h of blood collection, blood samples were cen-
trifuged at room temperature (18–25◦C) in a horizontal
rotor for 20min at 1500×g. After centrifugation, approxi-
mately half of the plasma was aspirated without disturbing
the whitish cell layer consisting of mononuclear cells and
platelets. The cell layer was collected with a Pasteur pipette
and transferred to a microcentrifuge tube.
2.4. Flow Cytometry of CD34+ Hematopoietic Stem and Pro-
genitor Cells. Hematological Cell Counts. The total number
of CD34+ cells from peripheral blood samples was measured
by ﬂow cytometry (Trucount, BD). For the two-platform
method, results were expressed as % CD34+ cells, and the
absolutenumberofCD34+ cellspermicroliterwascalculated
as % CD34+ cells × white blood cells × 103 μL. For the one-
platform method, the number of CD34+ cells per microliter
wascalculatedasCD34+ cells/μL=(numberofCD34+ cells ×
bead count per test × dilution factor)/number of beads
collected.
2.5. Sample Acquisition. Cells were acquired on a three-color
FACSCalibur ﬂow cytometer (BD) equipped with a 488-nm
argon laser and analyzed with CellQuest 3.1 software. TheJournal of Biomedicine and Biotechnology 3
Table 1: Demographics, CD34+ Cells, telomerase activity, and IGF1 concentration in control subjects.
Sample No. Age (y) Gender Duration (m) CD34 (%) Telomerase (U) IGF-1 (ng/mL)
Control
1 19 m 0 0.10 0.14 138.04
2 20 f 0 0.10 0.08 150.61
3 20 f 0 0.20 0.08 128.54
4 21 m 0 0.20 0.10 78.95
5 21 f 0 0.20 0.08 145.85
6 22 m 0 0.30 0.08 71.82
7 32 f 0 0.70 0.15 133.39
8 39 f 0 0.50 0.09 129.83
9 41 m 0 0.10 0.13 165.89
10 46 m 0 0.20 0.13 77.93
11 47 f 0 0.30 0.15 114.37
12 48 m 0 0.10 0.10 60.95
13 53 m 0 0.20 0.08 141.97
14 53 m 0 0.30 0.08 72.16
15 54 f 0 0.20 0.11 95.00
16 56 f 0 0.30 0.10 104.71
17 56 m 0 0.05 0.11 141.96
18 57 f 0 0.10 0.09 153.90
19 58 m 0 0.50 0.12 109.15
20 60 m 0 0.50 0.08 109.91
21 64 m 0 0.15 0.09 110.00
22 64 f 0 0.05 0.08 108.00
Average 43 54.5%# 0.24 0.10 115.59
SD 15.8 0.17 0.02 29.37
#The ratio of male.
instrument was aligned and calibrated daily using a three-
color mixture of CaliBRITE beads (BD) with FACSComp
software (BD). To comply with statistical requirements,
50,000 events were acquired for each sample in the Milan/
Mulhouse protocol [33]. For international society of hema-
totherapy and graft engineering (ISHAGE) (single and two
platform), a total of 100,000 leukocytes (G1) were col-
lected; for single-platform ISHAGE, 2,000 bead events were
collected.
2.6. Enzyme-Linked Immunosorbent Assay (ELISA) for IGF1.
Human IGF1 was determined by ELISA kit (Quantikine,
Minneapolis, MN, USA). Brieﬂy, the assay utilized mouse
anti-human IGF1 for immobilization on the microtiter wells
and goat anti-human IGF1 along with streptavidin conju-
gated to horseradish peroxidase for detection. The human
serum sample was allowed to react simultaneously with the
two antibodies, thus sandwiching the IGF1 molecules be-
tween the solid-phase and enzyme-linked antibodies. After
incubation, the wells were washed to remove unbound,
labeled antibodies. The horseradish peroxidase substrate
3,3 ,5,5 -tetramethylbenzidine (TMB) was added for devel-
opment of a blue color. This was stopped with the addition
of Stop Solution, changing the color to yellow. Absorbance
was measured spectrophotometrically at 450nm (Bio-TeK
Instruments, Winoski, VT). The concentration of IGF1 was
directly proportional to the color intensity of the test sample.
2.7. Analysis of Telomerase Activity (TRAP Assay). Analysis
of telomerase activity was assessed using the telomeric repeat
ampliﬁcation protocol (TRAP) assay [34] according to the
manufacturer’s protocol (Roche, Pleasanton, CA, USA). The
TRAP assay was performed on 30μg protein per sample
extract. Thirty cycles of PCR were performed at 94◦Cf o r
30s, 50◦Cf o r3 0s ,a n d7 2 ◦C for 90s. Sample absorbance was
measured at 450nm using a PowerWave × Microplate ELISA
Reader (Bio-TeK Instruments).
2.8. Statistical Analysis. Univariable, multivariable, and step-
wise regression analyses with two-sided t tests were used
to evaluate the eﬀect of 20070721-GX, gender, and age on
changes in number of CD34+ progenitor cells, IGF1 concen-
tration, and telomerase activity; P<0.05 was considered
statistically signiﬁcant.
3. Results
3.1. 20070721-GX-Induced Increase in Progenitor CD34+
Cells. Circulating cells were analyzed according to cell-
surface markers, with progenitor cells deﬁned as CD34+.
The number of CD34+ progenitor cells diﬀered signiﬁcantly
between the control and 20070721-GX groups (Figure 1(a),
Table 3, P<0.001). The average level of CD34+ progenitor
cells was about 6-fold higher in the 20070721-GX group
comparedwiththecontrolgroup(Tables1and2).Morethan4 Journal of Biomedicine and Biotechnology
Table 2: Demographics, CD34+ Cells, telomerase activity, and IGF1 concentration in 20070721-GX subjects.
Sample No. Age (y) Gender Duration (m) CD34 (%) Telomerase (U) IGF-1 (ng/mL)
20070721-GX
23 27 m 2 4.60 0.27 68.08
24 27 f 2 3.90 0.12 172.53
25 35 f 2 1.35 0.14 113.52
26 39 f 8 1.70 0.14 74.43
27 40 m 12 1.70 0.13 117.07
28 41 m 3 1.00 0.10 133.14
29 43 m 12 0.60 0.08 79.82
30 44 f 5 0.70 0.09 99.85
31 44 f 6 0.30 0.09 142.48
32 45 f 1.7 5.95 0.10 113.79
33 46 f 2 0.20 0.12 97.65
34 46 f 8 0.40 0.23 129.58
35 46 m 23 1.70 0.22 118.71
36 48 m 1.2 0.30 0.13 75.49
37 49 m 14 0.35 0.15 88.34
38 51 m 12 1.25 0.13 79.32
39 54 f 12 0.30 0.12 99.85
40 57 m 12 1.10 0.10 126.29
41 58 f 8 1.10 0.08 155.78
42 58 f 11 0.60 0.11 74.34
43 59 m 2 0.65 0.10 93.82
44 61 m 3 1.50 0.15 123.91
Average 46 50%# 1.42 0.13 108.08
SD 9.2 1.47 0.05 27.75
#The ratio of male.
half of 20070721-GX subjects (12/22, 54.5%) had more than
1% CD34+ progenitor cells in peripheral blood. Regression
analysis showed that 20070721-GX signiﬁcantly increased
the number of CD34+ progenitor cells in peripheral blood.
However, age, gender, and the duration of 20070721-GX
intake did not aﬀect the amount of CD34+ progenitor cells
(Table 3).
3.2. 20070721-GX-Induced Increase in Telomerase Activity.
With suﬃcient telomerase enzyme, it is possible to prevent
cells from dying. The clinical trials showed that telom-
erase activity diﬀered signiﬁcantly between the control and
20070721-GX groups (Figure 1(b), Table 4, P = 0.016).
The average telomerase activity increased about 30% in
the 20070721-GX group compared with the control group
(Tables 1 and 2). Regression analysis showed that 20070721-
GX signiﬁcantly increased telomerase activity in subjects.
The duration of 20070721-GX intake had a small but
signiﬁcant eﬀect on the increase in telomerase activity (β =
0.003, P = 0.022) using univariable regression analysis;
however, this was not signiﬁcant after adjusting other vari-
ables,anddurationwasconsequentlyexcludedfromstepwise
regression analysis. Age and gender did not aﬀect telomerase
activity (Table 4).
3.3. Eﬀect of 20070721-GX on Serum IGF1 Concentration. To
evaluate IGF1 concentrations in this cohort, we used ELISA.
Serum IGF1 ranged from 60 to 165ng/mL (mean, 115 ±
30ng/mL)amongcontrolsubjectsandfrom68to172ng/mL
(mean, 108 ± 28ng/mL) among the 20070721-GX subjects
(Tables 1 and 2). Although the average IGF1 concentration
in 20070721-GX subjects decreased slightly, it did not reach
statistical signiﬁcance (Figure 1(c), P = 0.40).
4. Discussion
To control the quality of each batch of the food supple-
ment of 20070721-GX, the placental extract component is
measured by ELISA. The evaluation includes concentrations
of progesterone (Pgt), estriol (E3), estradiol (E4), human
choronic gonodotropic (HCG), human placental lactogen
(hPL), and total protein (tPrt). For each batch, the concen-
trationsare10±5mg/mLtPrt,30±5ng/mLPgt,10±5ng/mL
E3, 10 ± 5ng/mL E4, 25 ± 5mIU/mL HCG, and 0.15 ±
0.1mg/L hPL. Batches that ﬁt these six indicators are
chosen into chemistry, manufacturing, and controls (CMCs)
manufacturingforstandardoperationandSGSexamination.
Because this placental extract is derived from pig at 8 weeks
pregnancy (full term is 20 weeks), it is full of nutrition andJournal of Biomedicine and Biotechnology 5
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Figure 1: Eﬀect of 20070721-GX on human rejuvenation. (a) Flow cytometric enumeration of CD34+ hematopoietic stem cells in control
and20070721-GX-treatedsubjects.(b)Telomeraseactivity(TRAPassay).(c)Enzyme-linkedimmunosorbentassayforIGF1.Datarepresent
means ± SEM. Diﬀerences between groups were examined by t test.
∗∗P < 0.05;
∗∗∗P < 0.001.
Table 3: Regression analysis for CD34+ cells.
Variable
Univariable Multivariable Stepwise
β (95% CI) Pβ (95% CI) Pβ (95% CI) P
20070721-GX 1.177 (0.527 ∼ 1.827) 0.001∗ 1.732 (0.851 ∼ 2.613) <0.001∗ 1.177 (0.527 ∼ 1.827) 0.001∗
Duration (months) 0.036 (–0.033 ∼ 0.105) 0.296 −0.068 (–0.151 ∼ 0.015) 0.106 Excluded
Male −0.153 (–0.899 ∼ 0.592) 0.680 0.052 (–0.597 ∼ 0.700) 0.873 Excluded
Age (years) −0.015 (–0.043 ∼ 0.014) 0.306 −0.018 (–0.043 ∼ 0.007) 0.157 Excluded
∗P<0.05 considered statistically signiﬁcant.
the peptide concentrations are relatively high compared with
other placental extracts collected at full term.
In our study, 95% (21/22) of individuals had an increase
of more than 20% of CD34+ stem cells in peripheral blood
compared with the control group (Tables 1 and 2). The
enhancing eﬀect was being observed in two elderly people
(Tables 1 and 2). One subject was 59 years old (no. 43) and
showed a 2.7-fold increase over control, and another was
61 years old (no. 44) with a 6.25-fold increase. In human,
CD34+ cells can increase by 15% in young people but not in
elderly people after taking exercise [15]. However, the food
supplement20070721-GXcanincreasehealthnotonlyinthe
youngbutalsoinmiddle-agedorolderpeople.Inthepresent
study, the CD34+ stem cells in peripheral blood of subjects
that took 20070721-GX (1.42 ± 1.50%) were signiﬁcantly
higher than in control subjects (0.24 ± 0.17%, P = 0.001)
(Tables 1 and 2).
In addition, the CD34+ status of two young individuals
increased 7 times and 24 times after taking the supplement
for only 2 months in comparison to the mean of the control
group (Tables 1 and 2). This result indicates that duration of
foodsupplementintakewasnotcloselyrelatedtotheincrease
in CD34+ cells (Table 3).
Other issues arise from this result. Is the increase in
CD34+ cells enough to repair injured cells or cause rejuve-
nation? According to a study by Khosrotehrani et al. [35], a
total of 701 male (XY+) microchimeric cells were identiﬁed
(mean [SD], 227 (128) XY+ cells per million maternal
cells [0.02%]). Interestingly, in maternal epithelial tissues
(thyroid, cervix, intestine, and gallbladder), 14% to 60% of
XY+ cells expressed cytokeratin. This result implied that only
a small amount of stem cells from the son is needed to
repair injured cells derived from maternal tissues. Stem cells
can not only transdiﬀerentiate diﬀerent organs, but they are
also involved in renewal and proliferation. Because this food
supplement increased CD34+ stem cells by 20% in 95% of
subjects, we suggest that it could play a role in repairing
injured tissue. Direct evidence, however, requires further
study.
Using the TRAP assay, we found that 2.2 to 2.3-fold (to
0.22–0.23U) increases in telomerase activity after two 46-
year-oldsubjects(nos.34and35)took20070721-GXfor8or6 Journal of Biomedicine and Biotechnology
Table 4: Regression analysis for telomerase activity.
Variable
Univariable Multivariable Stepwise
β (95% CI) Pβ (95% CI) Pβ (95% CI) P
20070721-GX 0.030 (0.006 ∼ 0.053) 0.016∗ 0.022 (–0.011 ∼ 0.055) 0.186 0.030 (0.006 ∼ 0.053) 0.016∗
Duration (months) 0.003 (0.000 ∼ 0.005) 0.022∗ 0.001 (–0.002 ∼ 0.004) 0.372 Excluded
Male 0.010 (–0.015 ∼ 0.035) 0.436 0.011 (–0.013 ∼ 0.035) 0.349 Excluded
Age (years) 0.000 (–0.001 ∼ 0.001) 0.422 −0.001 (–0.002 ∼ 0.000) 0.172 Excluded
∗P<0.05 considered statistically signiﬁcant.
23 months (Table 2). Although an increase in telomerase
activity has an antisenescence eﬀect, increasing telomerase
activity may also cause tumorigenesis [36, 37]. Therefore,
we measured the telomerase activity in two malignant brain
tumor cell lines: DBTRG and 8401. Telomerase activity in
these cells was 1.8U and 2.7U, respectively, which is much
higher than the average activity of 0.13U in the experimental
subjects. Furthermore, according to Fu and Chen [38],
telomerase activity in normal bone marrow is 0.3U, which
is close to the increased level of activity in our experimental
subjects.Theseresultssuggestthatthisfoodsupplementdoes
not cause tumorigenesis.
Telomerase activity is inversely related to senescence,
IGF1 is associated with rejuvenation, and CD34+ cells are
related to injured organ repair and anti-inﬂammatory activ-
ity. Thus, it is important to monitor the phenotypic features
of people taking food supplements. Skin became more ﬁne
and tight, and wrinkles decreased in some people. In addi-
tion, more energy, increased sexual impulses, and improve-
ment of menstrual disorder symptoms were described by
others. These features are related to rejuvenation and
antisenescence. Furthermore, decreased serum glutamic
oxaloacetic transaminase and serum glutamic pyruvic trans-
aminaseliverenzymesandimprovednasalallergies,arthritis,
and lower back pain were also observed. These features
could be related to anti-inﬂammatory activity and injured
cell repair. These phenotypic features are subjective and only
represent a preliminary ﬁnding but are worth noting when
designing future studies.
In our study, taking the food supplement increased the
number of CD34+ cells and increased telomerase activity,
but decreased IGF1 in the same subjects (nos. 23, 25, 26,
33, 36, 37, 38, 39, and 42; 9/22 = 40%). Thus, an important
issue is whether the placental extract aﬀects the same cellular
target in each case. Because there are so many compounds
in placental extract, it is possible that diﬀerent targets of
diﬀerent compounds may lead to three diﬀerent eﬀects.
However, because CD34+ stem cells have a relatively high
telomerase activity [39], these eﬀects are likely to be linked
in placental extract that likely aﬀects both. However, because
IGF1 is an independent biomarker for antisenescence, none
of the subjects that took the food supplement had only a
decrease in IGF1. The placental extract should be fraction-
ated to determine which components are responsible for
which eﬀects.
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